NIA Releases National Strategy for Alzheimer’s Clinical Trials Participation

As part of the “National Plan to Address Alzheimer’s Disease,” the National Institute on Aging (NIA) is taking steps towards a comprehensive, unified national strategy to fight Alzheimer’s in the United States. One of the main goals of the plan is to expand research efforts, specifically clinical trials.NIA Releases National Strategy for Participation in Alzheimer's Clinical Trials

The newly released strategy aims at diversifying and increasing participation in clinical trials. Read more about the national plan and how it will guide future Alzheimer’s clinical trials and research efforts.

NIA’s National Strategy to Fight Alzheimer’s and Increase Alzheimer’s Clinical Trials Participation

The NIA has been working for more than two years to gather practical and productive approaches to help Alzheimer’s clinical trials attract a higher number and more diverse participants.

The recently released, “National Strategy for Recruitment and Participation in Alzheimer’s Clinical Research” was a collaborative effort between multiple institutions, including the Alzheimer’s Association, the Global Alzheimer’s Platform (GAP) Foundation, the NIA and study participants.

The overall strategy focuses on four themes:

  1. Build and improve capacity and infrastructure at the study site level.
  2. Develop an applied science of recruitment.
  3. Engage local communities and support participants in Alzheimer’s clinical trials.
  4. Increase awareness and engagement at a broad, national level.

The Director of the NIA, Dr. Richard J. Hodes, summarizes the strategy, saying:

“What’s needed, they conclude, is concerted national action to create awareness and to support [Alzheimer’s clinical trials] study participation. The National Strategy offered here outlines concrete steps that each of us… can take to effect change. Some measures can be taken by individuals and organizations on their own and others through collaboration and coordination. This will require attention by both the public and private sectors.”

An integral part of developing the National Strategy, the GAP Foundation is focused on developing innovative strategies to better connect study participants to its network of Alzheimer’s research centers.

GAP Foundation President, John Dwyer, remarks,

“I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The GAP Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its network of leading academic and private research centers; forging partnerships with healthcare professionals to increase the participation of African Americans and Latinos; and breaking down barriers to faster, more efficient Alzheimer’s clinical trials.”

Do you think a cure for the disease will be found in Alzheimer’s clinical trials? Have you or a loved one participated in a clinical trial? We’d like to hear your stories and thoughts in the comments below.

Related Articles:

Please leave your thoughts and comments

  • Deepak Sharma

    Treatments for Alzheimer’s Disease
    Right now, there is no cure for Alzheimer’s disease. Once a person starts showing signs – memory loss and problems with learning, judgment, communication, and daily life — there aren’t any treatments that can stop or reverse them.

    But there are medicines that can ease some of the symptoms in some people. They can slow down how quickly the disease gets worse, and help the brain work better for longer. It’s important to talk to your doctor about which option may work best for you.

    How to Choose a Treatment
    Your doctor will help you choose the best treatment based on a few things about you, including:
    Your age, overall health, and medical history
    How severe your disease is
    How well a medicine or therapy will work for you and your lifestyle
    Your preferences or those of your family or caregivers

    What Medications Can Help?
    Some drugs curb the breakdown of a chemical in the brain, called acetylcholine, that’s important for memory and learning. They may slow down how fast symptoms get worse for about half of people who take them. The effect lasts for a limited time, on average 6 to 12 months. Common side effects are usually mild for these medications and include diarrhea, vomiting, nausea, fatigue, insomnia, loss of appetite, and weight loss. There are three drugs of this type: donepezil (Aricept), galantamine (Razadyne), and rivastigmine (Exelon). I will
    also suggest to take prescribed meds only because meds are easly avaibale online, I know some online stores like Ebay or mygenericpharmacy

About The Author

Profile photo of Alissa Sauer